EBITDA: Income before interest, taxes, depreciation and amortization.
Novartis AG (NVS) had EBITDA of $20.66B for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$51.72B |
|
$11.94B |
|
$12.83B |
|
$38.90B |
|
$37.18B |
|
$14.54B |
|
$-904.00M |
|
$13.64B |
|
$13.64B |
|
$11.94B |
|
$11.94B |
|
$11.94B |
|
$11.94B |
|
$14.54B |
|
|
EBITDA |
$20.66B |
2.02B |
|
2.04B |
|
$5.92 |
|
$5.87 |
|
| Balance Sheet Financials | |
$29.70B |
|
$9.46B |
|
$72.54B |
|
$102.25B |
|
$28.69B |
|
$21.37B |
|
$29.43B |
|
$58.12B |
|
$44.13B |
|
$-7.54B |
|
$44.13B |
|
1.98B |
|
| Cash Flow Statement Financials | |
$17.62B |
|
$-7.51B |
|
$-11.74B |
|
$13.39B |
|
$11.46B |
|
$-1.93B |
|
$1.04B |
|
$-7.62B |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.04 |
|
-- |
|
-- |
|
0.33 |
|
0.67 |
|
75.20% |
|
28.12% |
|
28.12% |
|
39.94% |
|
26.37% |
|
23.09% |
|
$16.34B |
|
-- |
|
-- |
|
-- |
|
0.51 |
|
2.24 |
|
6.85 |
|
53.32 |
|
27.06% |
|
-158.24% |
|
11.68% |
|
18.23% |
|
$22.34 |
|
$8.03 |
|
$8.66 |
|